Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

GW Pharmaceuticals Completes European Approval Procedure For Sativex

21st Oct 2013 08:41

LONDON (Alliance News) - GW Pharmaceuticals PLC said Monday that it had successfully closed the European mutual-recognition procedure in France for its Sativex treatment of spasticity caused by Multiple Sclerosis.

A mutual-recognition procedure means that GW Pharmaceuticals has been granted marketing authorisation by France, and that authorisation has been recognised by other EU members.

As a result, Sativex received recommendation for approval by French authorities. The company says the next step is to work with the French National Agency of Medicine and Health Products Safety to finalise any requirements specific to France.

"The successful completion of this regulatory process for Sativex in France maintains our positive regulatory track record for Sativex, which is already approved in 22 countries," said Chief Executive Officer Justin Gover in a statement. "We look forward to working with our partners, Almirall, towards the launch of Sativex in this important European country."

Shares in the pharmaceutical company were trading up 4.0% at 149.75 pence Monday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2013 Alliance News Limited. All Rights Reserved.


Related Shares:

GWP.L
FTSE 100 Latest
Value8,941.12
Change0.00